- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04601675
Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
October 20, 2020 updated by: He Eye Hospital
Randomized Study on Diabetic Macular Edema Patients Receiving Ranibizumab and Dexamethasone or Ranibizumab Only.
The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Ranibizumab or combination of Ranibizumab And Dexamethasone under pro re nata treatment regimen for Diabetic Macular Edema patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to evaluate the clinical outcome after intraocular injections of Ranibizumab or combination of Ranibizumab and Dexamethasone under pro re nata treatment regimen for the patients with Diabetic Macular Edema patients.
Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT), contrast sensitivity (CS) as well as predictive factors including best-corrected visual acuity (BCVA), vision related questionnaires and various other ocular parameters will be assessed.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jun Li, M.D., Ph.D.
- Phone Number: 0411-86525401
- Email: robin_lijun@sina.com
Study Contact Backup
- Name: Emmanuel E Pazo, M.D., Ph.D.
- Phone Number: 18612782131
- Email: ericpazo@outlook.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- He Eye Specialist Hospital
-
Sub-Investigator:
- Qiqi Zhong, M.D.
-
Sub-Investigator:
- Lanting Yang, M.D.
-
Contact:
- Jun Li, M.D.
- Phone Number: 15104083505
- Email: robin_lijun@sina.com
-
Contact:
- Emmanuel Eric E Pazo
- Phone Number: 18612782131
- Email: ericpazo@outlook.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients with diabetic retinopathy and centre involving DMO, as determined by using spectral domain optical coherence tomography (SD-OCT), in one or both eyes with:
- Central retinal subfield thickness of > 300 but < 400 microns as determined by SD-OCT due to diabetic macular oedema OR
- Central retinal subfield thickness of < 300 microns provided that intraretinal and/or subretinal fluid is present in the central subfield (central 1 mm) related to diabetic macular oedema AND
- Visual acuity of > 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent > 20/320)
- Amenable to laser treatment, as judged by the treating ophthalmologist
- Over 18 years of age
Exclusion Criteria:
Eyes of patients will not be included in the study if:
- The macular oedema is due to causes other than diabetic macular oedema such as epiretinal membrane, vitreomacular traction, vein occlusion, or others
- The eye is ineligible for macular laser treatment, as judged by the treating ophthalmologist
- The eye has DMO and central subfield retinal thickness (CST) of > 400 microns.
- The eye has activeA proliferative diabetic retinopathy (PDR) requiring treatment.
- The eye has received intravitreal Anti- Vascular Endothelical Growth Factor (Anti-VEGF) therapy within the previous two months.
- The eye has received macular laser treatment within the previous 12 months.
- The eye has received intravitreal injection of steroids.
- The eye has received cataract surgery within the previous six weeks
- The eye has received panretinal photocoagulation within the previous 3 months
- Patients on pioglitazone and the drug cannot be stopped 3 months prior to entering into the trial and for the duration of the study
- The patient has chronic renal failure requiring dialysis or kidney transplant
- The patient has any other condition that in the opinion of the investigator would preclude participation in the study (such as unstable medical status or severe disease that would make it difficult for the patient to be able to complete the study)
- The patient has very poor glycemic control and started intensive therapy within the previous 3 months
- The patient will use an investigational drug during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diabetic ME: Ranibizumab and intravitreal Dexamethasone
Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
|
Pro re nata patients with macula edema due to diabetes will receive Ranibizumab.
Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
Other Names:
|
Active Comparator: Diabetic ME: Ranibizumab
Participants with diabetic macular edema (ME) will receive Ranibizumab only.
|
Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in monocular BCVA in the treatment eye
Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters at baseline (pre-treatment) and 1 week, 1month, 2 months, 3 months, and 6 months after treatment.
|
Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Mean change in binocular BCVA
Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters at baseline (pre-treatment) and 1 week, 1month, 2 months, 3 months, and 6 months after treatment.
|
Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in central subfield retinal thickness
Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Mean change in central subfield retinal thickness in the study eye, as determined by spectral domain optical coherence tomography (OCT), from baseline to 6 months.
|
Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Change in Humphrey 10-2 visual field in the treatment eye
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean deviation (MD) of the Humphrey 10-2 visual field is assessed by a Humphrey 10-2 visual field test at baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
People meeting driving standards
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Percentage (%) of people meeting driving standards is assessed by an Esterman binocular visual field test at baseline and and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in NEI VFQ25
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Scores from NEI VFQ25 questionnaire will be assessed and compared at baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in EQ-5D 5L
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Scores from EQ-5D 5L questionnaire will be assessed and compared at baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in VisQoL scores
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Scores from VisQoL questionnaire will be assessed and compared at baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in wavefront aberrations
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean deviation (MD) of wavefront aberrations is assessed by Nidek OPD Scan III test at baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in ocular surface and tear-film
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean deviation (MD) of ocular surface and tear-film parameters is assessed by Oculus Keratographer test at baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean change in vessel density
Time Frame: Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Mean deviation (MD) of vessel density is assessed by Spectralis OCT2, Heidelberg-Engineering test at baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
|
Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Side effects
Time Frame: 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Side effects are measured by a review of the participant's medical and ophthalmic history.
|
1 week, 1 month, 2 months, 3 months, and 6 months.
|
Use of additional treatments (including laser)
Time Frame: 1 week, 1 month, 2 months, 3 months, and 6 months.
|
Use of additional treatments (including laser) is assessed by the treating ophthalmologist
|
1 week, 1 month, 2 months, 3 months, and 6 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Wei He, M.D., Ph.D., He Eye Specialist Hospital, Shenyang.
- Principal Investigator: Jun Li, M.D., Ph.D., He Eye Specialist Hospital, Shenyang.
- Study Director: Emmanuel E Pazo, M.D., Ph.D., He Eye Specialist Hospital, Shenyang.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 31, 2020
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
September 17, 2021
Study Registration Dates
First Submitted
October 20, 2020
First Submitted That Met QC Criteria
October 20, 2020
First Posted (Actual)
October 26, 2020
Study Record Updates
Last Update Posted (Actual)
October 26, 2020
Last Update Submitted That Met QC Criteria
October 20, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Macular Edema
- Edema
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Ranibizumab
Other Study ID Numbers
- ME-230620
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Hoffmann-La RocheRecruitingUveitic Macular EdemaKorea, Republic of, United Kingdom, China, United States, Netherlands, Canada, Israel, Austria, Brazil, Italy, Taiwan, Poland, Portugal, Mexico
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
Clinical Trials on Ranibizumab Ophthalmic and Intravitreal Dexamethasone
-
Medical University of ViennaCompletedAge-Related Macular Degeneration | Neovascularization, ChoroidalAustria
-
Universidad Autonoma de San Luis PotosíHospital Central "Dr. Ignacio Morones Prieto"CompletedEye Diseases | Premature Birth | Retinal Disease | Retinopathy of Prematurity Both EyesMexico
-
Beijing HospitalCompletedDiabetic Macular EdemaChina
-
University Hospital, Basel, SwitzerlandCompletedAge-Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
GlaxoSmithKlineCompletedMacular DegenerationUnited States, Australia, Italy, Belgium, Germany, Canada, Japan, Sweden, Denmark
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; AllerganCompleted
-
Peter A Campochiaro, MDGenentech, Inc.CompletedMacular Edema | Retinal Vein OcclusionUnited States
-
California Retina ConsultantsAllerganCompletedDiabetic Macular EdemaUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; Regeneron PharmaceuticalsCompletedDiabetic Macular EdemaUnited States
-
Brian Burke, MPHUnknownRetinal Vein OcclusionUnited States